Principal Investigator

---

Education

University of California, Davis

    --Fellowship in Endocrinology‑ July 1984 – June 1986

University of California, Irvine‑Long Beach VA

    -- Internship and Residency in Internal Medicine July 1981–June 1984

Loma Linda University Jan 1981 – Dec 1981

    --Doctor of Medicine awarded Dec 1981

University of Guadalajara Jan 1975 – Dec 1980

University of California, Santa Barbara

     --Bachelor of Arts in Biology awarded Sep 1977

Current and Previous Appointments

Associate Clinical Professor of Medicine,

University of California at San Francisco (since 1991-2015)

Nephrology Advisory Committee‑Fresno Community Hospital

Nominating Committee‑Fresno Madera Medical Society

President American Diabetes Association, San Joaquin Valley Chapter

Ethics Committee Fresno Community Hospital 

Staff Privileges

Saint Agnes Medical Center

Community Regional Medical Center - Fresno

Clovis Community Hospital

Medical Organization Memberships

Fellowship American College of Physicians

California Medical Association

Fresno‑Madera Medical Association

Licenses/Certifications

State of California‑License to practice as a physician and surgeon 

Certified Diabetes Educator, November 1986

American Board of Internal Medicine‑ Board Certified

Subspecialty in Endocrinology and Metabolism, Nov.1987

American Board of Internal Medicine, Board Certified

Specialty of Internal Medicine, Nov. 1984

Publications 

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-1662. doi:10.2337/dc09-0517

Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera). J Clin Endocrinol Metab. 2007;92(6):2211-2214. doi:10.1210/jc.2006-0631 

Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705. doi:10.2337/diacare.26.6.1701

Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study [published online ahead of print, 2020 Jul 30]. Diabetes Technol Ther. 2020;10.1089/dia.2020.0224. doi:10.1089/dia.2020.0224

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care. 2006;29(5):1016-1023. doi:10.2337/diacare.2951016

Inhaled insulin: a clinical perspective with emphasis on EXUBERA®. Expert Rev Endocrinol Metab. 2007;2(3):313-320. doi:10.1586/17446651.2.3.313

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34(10):2082-2090. doi:10.1016/j.clinthera.2012.09.007

A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl. 2012;33(4):601-607. doi:10.2164/jandrol.111.014308

Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. J Sex Med. 2014;11(3):857-864. doi:10.1111/jsm.12411

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes Obes Metab. 2017;19(11):1562-1569. doi:10.1111/dom.12972

Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clin Diabetes. 2017;35(2):90-95. doi:10.2337/cd15-0058

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291-2301. doi:10.1210/jc.2018-00070

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. doi:10.1111/dom.12937

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial [published correction appears in JAMA. 2016 May 17;315(19):2125. Tigkas, Stelios [corrected to Tigas, Stelios]] [published correction appears in JAMA. 2016 May 17;315(19):2125. Tigkas, Stelios [corrected to Tigas, Stelios]]. JAMA. 2016;315(9):898-907. doi:10.1001/jama.2016.1252

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017;318(1):45-56. doi:10.1001/jama.2017.7117

Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study [published online ahead of print, 2020 Jul 30]. Diabetes Technol Ther. 2020;10.1089/dia.2020.0224. doi:10.1089/dia.2020.0224

Controlled Trial of Transurethral Alprostadil in Diabetic and Non-Diabetic Men with Chronic Erectile Dysfunction (Impotence)‑ New England Journal of Medicine; January 2, 1997. N Engl J Med 1997; 336:1-7; DOI: 10.1056/NEJM199701023360101

Principle author‑American Diabetes Association ‑Presentation June 4, 1996

Multicenter Double‑blind, Placebo‑controlled Trial of Transurethral Alprostadil In Diabetic and Nondiabetic Men with Chronic Erectile Dysfunction (Impotence)

Treatment of Chronic Erectile Dysfunction with Transurethral Alprostadil in Diabetic and Non-Diabetic Men, Norwood et al. Diabetologia (1997) 40: [Suppl 1]: I‑V, page 591

Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. Journal of American Geriatrics Society Year 2001

Diabetes Care 2006; 29(5): 1016-1023. ©2006 American Diabetes Association, Inc. Posted 5/12/05 “Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels with Muraglitazar, a Dual (α/y) Peroxisone Proliferator-Activated Receptor Activator, in Patients with Type 2 Diabetes inadequately controlled with Metformin Monotherapy;

Diabetes Care 2003 26:1701-1705, ©2003 American Diabetes Association, Inc. “The efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers”

Expert Review of Endocrinology and Metabolism: Inhaled Insulin: A Clinical Perspective with Emphasis of EXUBERA® May 2007, Volume 2 No. 3 Pages 313-320.

Endojournals.org Randomized Study to Characterize Glycemic Control and Short-Term Pulmonary Function in Patients with Type 1 Diabetes Receiving inhaled insulin Journal of Clinical Endocrinology & Metabolism, 2007

Diabetes – Safety of Exenatide once weekly in patients with type II diabetes treated with a thiazolidinedione. 70th Scientific Session.2010 715-P 

Presentations

Doctors Guide to the Internet-Presentation September 13, 2005 “Impressive Efficacy and Safety Results seen with Inhaled Insulin (Exubera) in Type 1 Diabetics: Present at EASD.

Helsinki, Finland at the International Diabetes Federation is July of 1997.

Case Presentation Pregnancy Post Sheehans syndrome American College of Physicians

Meeting‑Monterey 1987

Research

Over 225 Clinical trials as Principal Investigator at Valley Research. 

Honors 

Distinction of fellowship in the American College of Physicians was awarded 1992 for continued research and medical teaching.

Extracurricular

Lecturer at numerous medical meetings mostly on the topics of hypertension, diabetes, depression, erectile dysfunction and obesity.

Contributor to the American Board of Internal Medicine‑ I help formulate and evaluate questions for the certification examination for the endocrinology, diabetes and metabolism section of the boards.

Honorary Speaker at many clubs and organizations: i.e. Rotary Club, Unitary Club, Elks, Veterans of Foreign Wars.

Languages

English and Spanish

References

Video: https://www.youtube.com/watch?v=-Ueoj-gOs5M

https://PaulNorwoodMD.blogspot.com/

https://hype.news/dr-paul-norwood-fresno-california-usa/home

https://hippocratesguild.com/dr-paul-norwood